Trial · NCT07656519

Consecutive Occupational Heat Exposure With and Without Overnight Cooling

NCT07656519, Not applicable, Recruiting, University of Ottawa

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Consecutive Occupational Heat Exposure With and Without Overnight Cooling. Trials, record NCT07656519. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07656519

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Consecutive Occupational Heat Exposure With and Without Overnight Cooling
NCT number: NCT07656519
Status: Recruiting
Phases: Not applicable
Enrollment: 10 participants, estimated
Lead sponsor: University of Ottawa
Conditions: Body Temperature Changes, Heat Stress, Heat Exposure, Heat Fatigue, Work Related Stress, Physiological Stress
Interventions: Simulated occupational heat exposure with recovery at recommended indoor temperature limit, Simulated occupational heat exposure with recovery in an overheated indoor environment
First posted: 2026-06-18
Last updated: 2026-10-05

Source ClinicalTrials.gov

Registered outcomes45

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Total work volume.	During each 240-minute morning and afternoon work bout on Day 1 and Day 2.	Total work completed during the 240-minute work protocol performed in the morning and afternoon work periods, expressed as cumulative minutes of work performed over the two consecutive work days. The work period consists of an initial continuous walking phase to a core temperature 38.0°C or 1°C increase above baseline resting (as measured prior to the start of the 2-day work protocol), followed by intermittent work-rest cycles. The morning and afternoon work periods are separated by a 1-hour recovery period.
Secondary	Time to core temperature of 38.0°C	During each 240-minute morning and afternoon work bout on Day 1 and Day 2.	Time, in minutes, from the start of continuous walking to the point at which core temperature reaches 38.0°C. Participants who do not reach 38.0°C before voluntary termination, reaching the applicable stopping criterion, or completing 240 minutes of continuous walking will have their time recorded at termination or completion.
Secondary	Time to 1.0°C increase in rectal temperature	During each 240-minute morning and afternoon work bout on Day 1 and Day 2.	Time, in minutes, from the start of continuous walking to the point at which rectal temperature increases by 1.0°C above baseline. For participant safety, continuous walking will not continue beyond a rectal temperature of 38.5°C. Therefore, for participants who reach 38.5°C before attaining a 1.0°C increase in rectal temperature, the time at which 38.5°C is reached will be recorded. Participants who voluntarily terminate exercise or complete 240 minutes of continuous walking before reaching either endpoint will have their time recorded at termination or completion.
Secondary	Average core temperature during work/rest cycles	During each 240-minute morning and afternoon work bout on Day 1 and Day 2.	Average core temperature measured during the intermittent work-rest cycles following the initial continuous work period.
Secondary	Heart rate at core temperature of 38.0°C	Each morning and afternoon work bout on Day 1 and Day 2.	Heart rate measured at the time a participant reaches a rectal temperature of 38.0°C during the initial continuous walking period. For participants who do not reach a rectal temperature of 38.0°C before voluntary termination, reaching the applicable stopping criterion, or completing 240 minutes of continuous walking, heart rate at termination or completion will be recorded.
Secondary	Heart rate at 1.0°C increase in core temperature	Each morning and afternoon work bout on Day 1 and Day 2.	Heart rate measured at the time a participant achieves a 1.0°C increase in core temperature above baseline during the initial continuous walking period. For participant safety, continuous walking will not continue beyond a core temperature of 38.5°C. Therefore, for participants who reach a core temperature of 38.5°C before attaining a 1.0°C increase above baseline, the heart rate at 38.5°C will be recorded. Participants who voluntarily terminate exercise or complete 240 minutes of continuous walking before reaching either endpoint will have their final recorded heart rate used.
Secondary	Average heart rate during work/rest cycles	During each 240-minute morning and afternoon work bout on Day 1 and Day 2.	Average heart rate measured during the intermittent work-rest cycles following the initial continuous work period.
Secondary	Mean skin temperature at core temperature of 38.0°C	Each morning and afternoon work bout on Day 1 and Day 2.	Mean skin temperature measured at the time a participant reaches a core temperature of 38.0°C during the initial continuous walking period. For participants who do not reach a core temperature of 38.0°C before voluntary termination, reaching the applicable stopping criterion, or completing 240 minutes of continuous walking, mean skin temperature at termination or completion will be recorded.
Secondary	Mean skin temperature at 1.0°C increase in core temperature	Each morning and afternoon work bout on Day 1 and Day 2.	Mean skin temperature measured at the time a participant achieves a 1.0°C increase in core temperature above baseline during the initial continuous walking period. For participant safety, continuous walking will not continue beyond a core temperature of 38.5°C. Therefore, for participants who reach a core temperature of 38.5°C before attaining a 1.0°C increase above baseline, the mean skin temperature at 38.5°C will be recorded. Participants who voluntarily terminate exercise or complete 240 minutes of continuous walking before reaching either endpoint will have their final recorded mean skin temperature used.
Secondary	Average mean skin temperature during work/rest cycles	During each 240-minute morning and afternoon work bout on Day 1 and Day 2.	Average mean skin temperature measured during the intermittent work-rest cycles following the initial continuous work period.

1 to 10 of 45Source ClinicalTrials.gov

See all 45 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
38329752	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Stroop Color-Word Test	Secondary outcome

Source ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07656519

GET https://conductscience.org/api/trials/v1/NCT07656519/registered?page=2

API reference For AI assistants